ABSK-061

N/A

Report date: 2026/03/31 20:00:21
NME

Base Information

Drug NameABSK-061
Drug Alias Nameselective small molecular inhibitor of fibroblast growth factor receptor 2 (FGFR2) and fibroblast growth factor receptor 3 (FGFR3)ABSK061
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFibroblast growth factor receptor 2 antagonistsFibroblast growth factor receptor 3 antagonists
TargetsFibroblast growth factor receptor 2Fibroblast growth factor receptor 3
Therapy Area/IndicationsSolid tumoursAchondroplasiaCarcinoma, Non-Small-Cell Lung +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesABbisko Therapeutics Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesABbisko Therapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursAchondroplasiaCarcinoma, Non-Small-Cell Lung +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A